BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

561 related articles for article (PubMed ID: 12384565)

  • 1. Preoperative blood reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy.
    Shariat SF; Gottenger E; Nguyen C; Song W; Kattan MW; Andenoro J; Wheeler TM; Spencer DM; Slawin KM
    Cancer Res; 2002 Oct; 62(20):5974-9. PubMed ID: 12384565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early postoperative peripheral blood reverse transcription PCR assay for prostate-specific antigen is associated with prostate cancer progression in patients undergoing radical prostatectomy.
    Shariat SF; Kattan MW; Song W; Bernard D; Gottenger E; Wheeler TM; Slawin KM
    Cancer Res; 2003 Sep; 63(18):5874-8. PubMed ID: 14522912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of metastatic prostate cancer using a splice variant-specific reverse transcriptase-polymerase chain reaction assay for human glandular kallikrein.
    Slawin KM; Shariat SF; Nguyen C; Leventis AK; Song W; Kattan MW; Young CY; Tindall DJ; Wheeler TM
    Cancer Res; 2000 Dec; 60(24):7142-8. PubMed ID: 11156423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of immunohistochemistry with reverse transcription-PCR for the detection of micrometastatic prostate cancer in lymph nodes.
    Shariat SF; Roudier MP; Wilcox GE; Kattan MW; Scardino PT; Vessella RL; Erdamar S; Nguyen C; Wheeler TM; Slawin KM
    Cancer Res; 2003 Aug; 63(15):4662-70. PubMed ID: 12907647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of micrometastatic prostate cancer cells in the lymph nodes by reverse transcriptase polymerase chain reaction is predictive of biochemical recurrence in pathological stage T2 prostate cancer.
    Okegawa T; Nutahara K; Higashihara E
    J Urol; 2000 Apr; 163(4):1183-8. PubMed ID: 10737491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of circulating prostate cells by reverse transcriptase-polymerase chain reaction of human glandular kallikrein (hK2) and prostate-specific antigen (PSA) messages.
    Corey E; Arfman EW; Oswin MM; Melchior SW; Tindall DJ; Young CY; Ellis WJ; Vessella RL
    Urology; 1997 Aug; 50(2):184-8. PubMed ID: 9255285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of circulating prostate specific antigen expressing prostatic cells in the bone marrow of radical prostatectomy patients by sensitive reverse transcriptase polymerase chain reaction.
    Gao CL; Dean RC; Pinto A; Mooneyhan R; Connelly RR; McLeod DG; Srivastava S; Moul JW
    J Urol; 1999 Apr; 161(4):1070-6. PubMed ID: 10081840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The value of a reverse transcriptase polymerase chain reaction assay in preoperative staging and followup of patients with prostate cancer.
    Ellis WJ; Vessella RL; Corey E; Arfman EW; Oswin MM; Melchior S; Lange PH
    J Urol; 1998 Apr; 159(4):1134-8. PubMed ID: 9507816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of prostate specific transcripts in the peripheral blood during brachytherapy predicts postoperative PSA kinetics.
    Mabjeesh NJ; Amir S; Stenger A; Chen J; Matzkin H
    Prostate; 2009 Aug; 69(11):1235-44. PubMed ID: 19434652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [RT-PCR assay for detecting PSA mRNA in peripheral blood of prostate cancer patients].
    Okubo Y; Ito T
    Hinyokika Kiyo; 1999 Jan; 45(1):25-30. PubMed ID: 10086262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.
    Haese A; Vaisanen V; Lilja H; Kattan MW; Rittenhouse HG; Pettersson K; Chan DW; Huland H; Sokoll LJ; Partin AW
    J Urol; 2005 Mar; 173(3):752-6. PubMed ID: 15711262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer.
    Stephan C; Jung K; Nakamura T; Yousef GM; Kristiansen G; Diamandis EP
    Int J Urol; 2006 Mar; 13(3):238-43. PubMed ID: 16643616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative reverse transcriptase polymerase chain reaction for prostate specific antigen predicts treatment failure following radical prostatectomy.
    Olsson CA; de Vries GM; Raffo AJ; Benson MC; O'Toole K; Cao Y; Buttyan RE; Katz AE
    J Urol; 1996 May; 155(5):1557-62. PubMed ID: 8627821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reverse transcriptase polymerase chain reaction for prostate specific antigen in the management of prostate cancer.
    Gomella LG; Raj GV; Moreno JG
    J Urol; 1997 Aug; 158(2):326-37. PubMed ID: 9224297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Similar rates of exponential decrease in serum concentrations of free prostate-specific antigen (PSA), PSA complexed to alpha-1-antichymotrypsin, and human glandular kallikrein 2 (hK2) in prostate cancer patients treated with GnRH-analogues.
    Björk T; Schalken J; Wittjes W; Ljungberg B; Lilja H
    Prostate; 2001 Apr; 47(1):14-20. PubMed ID: 11304725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative real-time reverse transcription: polymerase chain reaction of prostate-specific antigen (PSA) for detection of circulating prostatic cells in patients with clinically localized prostate cancer.
    Llanes L; Ferruelo A; Luján M; Pascual C; García-Mediero JM; Berenguer A
    Prostate Cancer Prostatic Dis; 2005; 8(3):248-52. PubMed ID: 15897916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PSA in the new millennium: a powerful predictor of prostate cancer prognosis and radical prostatectomy outcomes--results from the SEARCH database.
    Freedland SJ; Hotaling JM; Fitzsimons NJ; Presti JC; Kane CJ; Terris MK; Aronson WJ; Amling CL
    Eur Urol; 2008 Apr; 53(4):758-64; discussion 765-6. PubMed ID: 17868976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and molecular followup after radical retropubic prostatectomy.
    Oefelein MG; Ignatoff JM; Clemens JQ; Watkin W; Kaul KL
    J Urol; 1999 Aug; 162(2):307-10; discussion 310-1. PubMed ID: 10411026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of combined "triple"-reverse transcription-PCR analysis for prostate-specific antigen, human kallikrein 2, and prostate-specific membrane antigen mRNA in peripheral blood and lymph nodes of prostate cancer patients.
    Kurek R; Nunez G; Tselis N; Konrad L; Martin T; Roeddiger S; Aumüller G; Zamboglou N; Lin DW; Tunn UW; Renneberg H
    Clin Cancer Res; 2004 Sep; 10(17):5808-14. PubMed ID: 15355910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive value of primary Gleason pattern 4 in patients with Gleason score 7 tumours treated with radical prostatectomy.
    Khoddami SM; Shariat SF; Lotan Y; Saboorian H; McConnell JD; Sagalowsky AI; Roehrborn CG; Koeneman KS
    BJU Int; 2004 Jul; 94(1):42-6. PubMed ID: 15217428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.